Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 801-093-8 | CAS number: 1315251-11-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No experimental toxico-kinetic data are available for assessing adsorption, distribution, metabolism and excretion of the substance. Sinfonide is expected to be readily absorbed via the oral, inhalation and dermal route. For route to route extrapolation the final absorption percentages derived are: 50% oral absorption, 100% inhalation absorption and 10% dermal absorption.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 10
- Absorption rate - inhalation (%):
- 100
Additional information
Toxico-kinetic information on Sinfonide
Introduction
Sinfonide (CAS# 1315251-11-6) is a mono-constituent substance which is a pyrimidine derivative. Sinfonide has a molecular weight of 242.36 g/mol, and is a solid with a melting point of 70.7 ± 0.5°C, a boiling point of 335 ± 1.0 °C, a water solubility of 3.95 mg/L, a vapour pressure of 0.016 Pa and a log Kow of 5.11.
Absorption
Oral route: In an oral (gavage) repeated dose (OECD 407) and a reproduction/developmental toxicity screening test (OECD 421), systemic effects were observed in exposed animals. The effects on liver, pituitary and thyroid weights, and microscopic findings in the liver and stomach indicate that Sinfonide is absorbed via the oral route. Based on the molecular weight (242.36 g/mol), the high log Kow (5.11) and low water solubility (3.95 mg/L) absorption through the gut is expected. Lipophilic compounds may be absorbed into the lymphatic system in form of micelles. According to Martinez and Amidon (2002) the optimal log Kow for oral absorption falls within a range of 2-7. All this information indicates that Sinfonide is likely to be absorbed orally. The oral absorption is assumed to be 50%.
Dermal route: Based on the partition coefficient (Log Kow 5.11) and molecular weight (242.36 g/mol), the dermal absorption is anticipated to be maximally 10%, according to ECHA R.7.12 guidance. In addition, based on the LD50 values determined in the oral and acute toxicity studies (500 mg/kg bw and > 2000 mg/kg bw, respectively), it could be argued that the dermal absorption is at least 4 times less than the oral absorption. Therefore, the dermal absorption rate is considered to 10%.
Inhalation route: Absorption via the lungs is also indicated based on physico-chemical properties. Though the inhalation exposure route is thought minor, because of its low volatility (0.016 Pa), the octanol/water partition coefficient (Log Kow 5.11), indicates that inhalation absorption is possible. The blood/air (BA) partition coefficient is another partition coefficient indicating lung absorption. Buist et al. 2012 have developed BA model for humans using the most important and readily available parameters:
Log PBA = 6.96 – 1.04 Log (VP) – 0.533 (Log) Kow – 0.00495 MW.
For Sinfonide the B/A partition coefficient would result in:
Log P (BA) = 6.96 – 1.04 Log (0.016) – 0.533 x 5.11 – 0.00495 x 242.36 = 6.96 + 1.868 – 2.724 – 1.2 = 4.9
This means that the substance has a high tendency to go from air into the blood. It should, however, be noted that this regression line is only valid for substances which have a vapour pressure > 100 Pa. Despite Sinfonide being somewhat out of the applicability domain and the exact B/A may not be fully correct, it can be assumed that the substance will be absorbed via the inhalation route and will be close to 100%. An acute inhalation toxicity study (Harlan, 2014) is also available where systemic effects are observed.
Distribution
The log Kow of 5.11 (lipophilic) would suggest that the substance would pass through the biological membranes. Furthermore, the systemic effects of oral administration of Sinfonide, such as liver, pituitary and thyroid weight changes along with macro- and microscopical changes in the liver suggest that the substance is present in these organs after oral exposure.
The high lipophilicy of Sinfonide (log P>4) suggests a potential for the substance to accumulate in the adipose tissue of individuals that are frequently exposed. The predicted metabolism of the substance would limit the accumulation in the body fat and therefore there is no bioaccumulation for air-breathing animals, see below.
Metabolism
There are no experimental data on the metabolism of Sinfonide. The pyrimidine ring with two nitrogens can be protonated under acidic conditions (one nitrogen at the time) such as existing in the stomach deprotonated in the gut. This protonated nitrogen is a fairly strong acid with a pKa of 2.53 and may cause the irritancy in the stomach as seen in the gavage DRF (SPARC calculation attached).
In the liver, the following CYP450-mediated reactions are predicted by ToxTree (v 3.1.0.): aliphatic hydroxylation and N-oxidation (Fig.1). Furthermore, based on the modelling performed by Xenosite UGT v.1 (Dang et al., 2016), the nitrogens are likely to be the sites for UGT-mediated glucuronidation (Fig. 2). Sinfonide is not assumed to form any reactive metabolites based on predictions made with Xenosite Reactivity v.1 (Hughes et al., 2015; 2016)
Figure 1. Anticipated phase I (CYP-mediated) metabolism of Sinfonide (ToxTree v 3.1.0).
Figure 2. Predicted sites of UGT-mediated glucuronidation of Sinfonide (Xenosite UGT v.1)
Excretion
Sinfonide is likely to be excreted via the urine in the form of glucuronic acid metabolites. As a glucuronide the substance may also be excreted via bile, and may undergo (some) enterohepatic circulation.
Discussion
The substance is expected to be readily absorbed, orally, via inhalation (although the exposure is expected to be low based on the low vapour pressure), and to less extent via the dermal route based on the human toxicological information and physico-chemical parameters. Sinfonide is absorbed orally and metabolism in the liver is anticipated (see metabolism paragraph). The substance is anticipated to become present in the body upon oral administration based on acute and long-term animal studies available. Due to metabolism it will not accumulate in body fat.
For route to route extrapolation
Oral to dermal extrapolation: There are adequate data via the oral route and the critical toxic effect is related to systemic effects and therefore route to route extrapolation is applicable. The toxicity of the substance will be due to the parent compound but also to its metabolites. The overriding principle will be to avoid situations where the extrapolation of data would underestimate toxicity resulting from human exposure to a chemical by the route to route extrapolation. The toxicity of the dermal route will not be underestimated because absorption will be slower and the compound will also pass the liver. Therefore it will be assumed that the oral absorption is 50%, while the dermal extrapolation was calculated to be maximum of 10% will equal dermal absorption.
Oral to inhalation extrapolation
Though the substance is not a volatile liquid the inhalation exposure will be considered. The substance is not a corrosive for skin and eye and the systemic effect will overrule the effects at the site of contact. In the absence of bioavailability data it is most precautionary that 100% of the inhaled vapour is bioavailable. For the oral absorption 50% has been used for route to route extrapolation to be precautionary for the dermal route. For inhalation absorption 100% will be used for route to route extrapolation, because this will be precautionary for the inhalation route.
Conclusion
The substance is expected to be readily absorbed via the oral and inhalation route and somewhat lower via the dermal route based on toxicity and physico-chemical data. Using the precautionary principle for route to route extrapolation the final absorption percentages derived are: 50% oral absorption, 10% dermal absorption and 100% inhalation absorption.
References
Buist, H.E., Wit-Bos de, L., Bouwman, T., Vaes, W.H.J., 2012, Predicting blood:air partion coefficient using basis physico-chemical properties, Regul. Toxicol. Pharmacol., 62, 23-28.
Dang, N. L, Hughes, T. B., Krishnamurthy, V., and Swamidass, S. J. (2016). A Simple Model Predicts UGT-Mediated Metabolism. Bioinformatics, DOI: 10.1093/bioinformatics/btw350
Hughes, T. B., Miller, G. P., Swamidass, S. J. (2015). Site of Reactivity Models Predict Molecular Reactivity of Diverse Chemicals with Glutathione. Chemical Research in Toxicology, 28(4), 797-809.
Hughes, T. B., Dang, N. L., Miller, G. P., Swamidass, S. J. (2016). Modeling Reactivity to Biological Macromolecules with a Deep Multitask Network. ACS Central Science, DOI: 10.1021/acscentsci.6b00162
Martinez, M.N., and Amidon, G.L., 2002, Mechanistic approach to understanding the factors affecting drug absorption: a review of fundament, J. Clinical Pharmacol., 42, 620-643.
SPARC calculation: http://archemcalc.com/sparc-web/calc/popup/CalculationReport, calculated September, 2021
Xenosite metabolic predictor: https://swami.wustl.edu/xenosite/p/ugt.Contact; site visited September 2021.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.